A growing family: Adding mutated Erbb4 as a novel cancer target

摘要: As the upward spiral of novel cancer gene discoveries and molecular compounds continues to accelerate, a repetitive theme in drug development remains lack activity initially promising agents when given patients clinical trials. It is however invigorating that few targeted directed against select group ‘cancer superfamilies’ have escaped this all common fate, evolved into novel, clinically meaningful therapy strategies. Targeting dysregulated signaling epidermal growth factor family transmembrane receptors (Erbb family) has encompassed over last decade an ever increasing role personalized treatment approaches number human malignancies. Erbbs are receptor tyrosine kinases important regulators several pathways. Two its members (Erbb1/EGFR Erbb2/HER2) previously been shown be somatically mutated large fraction cancers. To determine if ...